Explore relationships stated by the original sources. Each number opens its exact collection—not a count of extra papers or proven treatments.
FDA application actionOctober 13, 2021
Pembrolizumab
Approved submission · SUPPL 122
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionOctober 13, 2021
Pembrolizumab
Approved submission · SUPPL 122
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionOctober 12, 2021
propofol
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionOctober 8, 2021
Sildenafil citrate
Approved submission · SUPPL 3
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionSeptember 29, 2021
Decitabine
Approved submission · SUPPL 3
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionSeptember 29, 2021
Decitabine
Approved submission · SUPPL 4
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionSeptember 29, 2021
Decitabine
Approved submission · SUPPL 5
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionSeptember 29, 2021
Decitabine
Approved submission · SUPPL 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionSeptember 29, 2021
Decitabine
Approved submission · SUPPL 2
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionSeptember 29, 2021
Decitabine
Approved submission · SUPPL 3
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionSeptember 20, 2021
Decitabine
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionSeptember 10, 2021
hydrochlorothiazide
Approved submission · SUPPL 80
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionSeptember 9, 2021
Cyclophosphamide
Approved submission · SUPPL 2
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 31, 2021
Pembrolizumab
Approved submission · SUPPL 117
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 31, 2021
Pembrolizumab
Approved submission · SUPPL 117
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 31, 2021
Pembrolizumab
Approved submission · SUPPL 118
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 31, 2021
Pembrolizumab
Approved submission · SUPPL 118
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 25, 2021
Everolimus
Approved submission · SUPPL 3
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 25, 2021
Cyclophosphamide
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 17, 2021
Nystatin
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 10, 2021
Nystatin
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 10, 2021
Pembrolizumab
Approved submission · SUPPL 102
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 10, 2021
Pembrolizumab
Approved submission · SUPPL 102
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 9, 2021
Sirolimus
Approved submission · SUPPL 86
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →